Julien Meissonnier
Chief Tech/Sci/R&D Officer presso CATALENT, INC.
Profilo
Fondatore di Accellix, Inc., Julien Meissonnier occupa attualmente la posizione di presidente e direttore di Accellix, Inc. e di Chief Scientific Officer e vicepresidente di Catalent, Inc. (una filiale di Catalent, Inc.). In precedenza ha occupato la posizione di Presidente & Amministratore Delegato di Cardio Ventures Ltd., Manager-Business Development presso Sol-Gel Technologies Ltd., Director-Marketing & Business Development presso Evogene Ltd., Manager-Global Marketing presso Novartis AG e Manager-Global Marketing presso Ciba-Geigy AG (una controllata di Novartis AG) e Development Engineer presso Rhone-Poulenc SA. Ha conseguito una laurea presso l'Università di Washington e un MBA presso l'INSEAD.
Posizioni attive di Julien Meissonnier
Società | Posizione | Inizio |
---|---|---|
CATALENT, INC. | Chief Tech/Sci/R&D Officer | 19/11/2019 |
Accellix, Inc.
Accellix, Inc. Medical SpecialtiesHealth Technology Accellix, Inc. develops in-vitro diagnostic systems. Its Accellix platform is an affordable tabletop diagnostic device with single-use assay cartridges that does not require extensive training nor involve complex operational processes. The firm’s product is an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test. The company was founded in 2009 by Julien Meissonnier and Harvey Kasdan and is headquartered in San Jose, CA. | Founder | 01/01/2009 |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Precedenti posizioni note di Julien Meissonnier
Società | Posizione | Fine |
---|---|---|
Cardio Ventures Ltd.
Cardio Ventures Ltd. Investment ManagersFinance Cardio Ventures Ltd is a venture capital firm. The firm headquartered in Jerusalem, Israel. | Chief Executive Officer | 01/01/2011 |
SOL-GEL TECHNOLOGIES LTD. | Corporate Officer/Principal | - |
NOVARTIS AG | Sales & Marketing | - |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Sales & Marketing | - |
EVOGENE LTD. | Sales & Marketing | - |
Formazione di Julien Meissonnier
University of Washington | Graduate Degree |
INSEAD | Masters Business Admin |
École Nationale Supérieure d'Ingénieurs de Caen | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
NOVARTIS AG | Health Technology |
SOL-GEL TECHNOLOGIES LTD. | Health Technology |
EVOGENE LTD. | Health Technology |
CATALENT, INC. | Health Technology |
Aziende private | 5 |
---|---|
Accellix, Inc.
Accellix, Inc. Medical SpecialtiesHealth Technology Accellix, Inc. develops in-vitro diagnostic systems. Its Accellix platform is an affordable tabletop diagnostic device with single-use assay cartridges that does not require extensive training nor involve complex operational processes. The firm’s product is an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test. The company was founded in 2009 by Julien Meissonnier and Harvey Kasdan and is headquartered in San Jose, CA. | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
Rhone-Poulenc SA | Process Industries |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
Cardio Ventures Ltd.
Cardio Ventures Ltd. Investment ManagersFinance Cardio Ventures Ltd is a venture capital firm. The firm headquartered in Jerusalem, Israel. | Finance |
- Borsa valori
- Insiders
- Julien Meissonnier